Single Doses of MK-8507, a Novel HIV-1 NNRTI, Reduced HIV Viral Load for at Least a Week

Wendy Ankrom1; Dirk Schürmann2; Deanne Jackson Rudd1; Andrea Schaeffer1; Inge De Lepeleire1; Evan J. Friedman1; Martine Robberechts1; Salijan Zhang2; Christian Keicher3; Joerg Hofmann1; S. Aubrey Stock1; Marian Iwamoto1

1Merck & Co., Inc., Kenilworth, NJ, USA; 2Charité Research Organisation, Berlin, Germany; 3MSD (Europe) Inc., Brussels, Belgium; 4Institute of Virology, Charité Universitätsmedizin Berlin, Berlin, Germany

Presented at HIV Glasgow (Virtual event); 5–8 October 2020.

ACKNOWLEDGMENTS
We thank all the participants in this study. The contributions of the investigators and their staff are also gratefully recognized. All authors met the ICMJE authorship criteria. Neither honoraria nor payments were made for authorship. Medical writing and editorial assistance was provided by ApotheCom (UK). This assistance was funded by MSD.

REFERENCES

Copyright © 2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved.